Therapeutics News

The FDA today announced the availability of a draft guidance describing its proposal on the nonproprietary naming of biological products.

Researchers found no significant differences between the intraocular pressure-lowering efficacy of polyquaternium-1-preserved travoprost and benzalkonium chloride-preserved travoprost when treating patients with open-angle glaucoma or ocular hypertension.

SEATTLE – Up to 70% of patients with retinitis pigmentosa can have cystoid macular edema, so thorough subjective and objective testing is advised, a presenter said here at Optometry’s Meeting.

Researchers recommended that eye care providers reconsider topical steroids for children as a primary treatment option or monitor them closely, in a study recently published in the British Journal of Ophthalmology.

The Protocol T study from the Diabetic Retinopathy Clinical Research Network was funded by the NIH as a long-term evaluation to answer the question of whether Lucentis, Eylea or Avastin is superior for treating various forms of retinopathy.

Eleven Biotherapeutics announced that a phase 2 exploratory study of EBI-005 showed significant improvements in ocular itching and tearing and associated nasal symptoms.

The market for glaucoma pharmaceuticals is predicted to remain flat until 2016, when growth will begin as a result of the introduction of new products.

Patients with chronic superficial punctate keratitis demonstrated improvement after switching from benzalkonium chloride-preserved latanoprost to SofZia-preserved travoprost, according to a study recently published in the Journal of Glaucoma.

Degradation of dexamethasone in drug eluting contact lenses was minimized by using vitamin E or a UV blocking contact lens, according to a study recently published in Optometry and Vision Science.

Establishing a pharmacist-managed medication refill clinic decreased workloads for physicians, and improved refill-request processing time and patient care, according to recently published data.